Diurnal Group PLC Director Dealings (1446F)
14 Julio 2021 - 1:00AM
UK Regulatory
TIDMDNL
RNS Number : 1446F
Diurnal Group PLC
14 July 2021
14 July 2021
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces the following Director's dealing:
Martin Whitaker, Chief Executive Officer, sold 80,612 Ordinary
Shares at a price of 63 pence per Ordinary Share in order to fund a
portion of his personal tax liability arising from the vesting of
his deferred bonus award of 376,230 Ordinary Shares, as detailed in
the RNS announcement dated 9 July 2021. Following the sale of
shares the total beneficial interest of Martin Whitaker and his
connected parties is 899,441 Ordinary Shares, representing 0.53% of
the total voting rights.
Richard Bungay, Chief Financial Officer, sold 105,798 Ordinary
Shares at a price of 63 pence per Ordinary Share in order to fund
his personal tax liability arising from the vesting of his deferred
bonus award of 225,738 Ordinary Shares, as detailed in the RNS
announcement dated 9 July 2021. Following the sale of shares the
total beneficial interest of Richard Bungay is 234,192 Ordinary
Shares, representing 0.14% of the total voting rights.
Details of the full notifications received by the Company are
set out below:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Martin Whitaker
------------------------------------- -----------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Diurnal Group plc
------------------------------------- -----------------------------------------
b) LEI 213800I2HNUNZN1LDH29
------------------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale of ordinary shares
------------------------------------- -----------------------------------------
c) Price(s) and volume(s)
------------------- -----------------
Price(s) Volume(s)
------------------- -----------------
63 pence 80,612
-------------------------------------------------------------- -----------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 13 July 2021
------------------------------------- -----------------------------------------
f) Place of the transaction XLON
------------------------------------- -----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Bungay
------------------------------------- -----------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Diurnal Group plc
------------------------------------- -----------------------------------------
b) LEI 213800I2HNUNZN1LDH29
------------------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale of ordinary shares
------------------------------------- -----------------------------------------
c) Price(s) and volume(s)
------------------- -----------------
Price(s) Volume(s)
------------------- -----------------
63 pence 105,798
-------------------------------------------------------------- -----------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 13 July 2021
------------------------------------- -----------------------------------------
f) Place of the transaction XLON
------------------------------------- -----------------------------------------
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Sole Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Alex Davis
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty
pharmaceutical company dedicated to developing hormone therapeutics
to aid lifelong treatment for rare and chronic endocrine
conditions, including congenital adrenal hyperplasia, adrenal
insufficiency, hypogonadism and hypothyroidism. Its expertise and
innovative research activities focus on circadian-based
endocrinology to yield novel product candidates in the rare and
chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFFFIFDFIVLIL
(END) Dow Jones Newswires
July 14, 2021 02:00 ET (06:00 GMT)
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
